Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05185297
Other study ID # UMSFRH/BD/143729/2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 17, 2021
Est. completion date December 19, 2022

Study information

Verified date February 2023
Source University Institute of Maia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Arterial hypertension (HT) was the leading global contributor for premature deaths in 2015. Its treatment includes medication and lifestyle changes, namely diet and regular exercise, which has shown to have an inverse relationship with arterial HT. Recreational soccer (RS) has proven to be a non-pharmacological treatment for several chronic conditions, including arterial HT, with meaningful decreases on blood pressure (BP). Recreation futsal (RF) is expected to elicit comparable BP changes to RS considering that it imposes similar physical and physiological demands. However, the effects of RF on BP and other cardiovascular markers have not been previously investigated in participants only with controlled arterial HT. Furthermore, acute BP changes and double product elicited by this exercise modality were never described. Therefore, the main purpose of this study is to assess if RF is an effective coadjuvant intervention for BP control in adults with controlled arterial HT. Secondary purposes are: i) to determine the impact of RF on other cardiovascular markers; ii) to describe the acute BP changes and the double product elicited by RF; and iii) to assess the impact of 1 month of detraining on BP and other cardiovascular markers (4 months).


Description:

Statistical analysis: The efficacy of the intervention will be assessed by comparing the differences between groups at follow-up, adjusted for the outcome baseline values, systolic blood pressure, maximum oxygen consumption and age (ANCOVA). Intention-to-treat approach will be the main analysis. The missing data will be imputed by using multiple linear regression. A per protocol analysis will also be performed (intervention group: attendance of at least 62.5% of the training sessions; control group: participants that did not engage in regular and supervised physical exercise or had an increase in dose or number of antihypertensive medication). The significance level will be set at 5%. Randomization: Stratified by baseline systolic blood pressure and maximum oxygen consumption. Contingency plan: If the recruitment rate is below than expected, potential measures are to include: i) 30-35- and 60-65-year-old participants; ii) participants with pre-hypertension or uncontrolled hypertension.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 19, 2022
Est. primary completion date October 31, 2022
Accepts healthy volunteers No
Gender Male
Age group 35 Years to 60 Years
Eligibility Inclusion Criteria: - Medicated controlled hypertension, with habitual SBP below 140 mmHg and DBP below 90 mmHg; - Males with 35-60 years; - Not being engaged in regular and supervised physical exercise in the last 6 months; - Medical clearance; - Vaccinated against SARS-COV-2. Exclusion Criteria: - Cardiovascular disease (heart failure), cerebrovascular disease, advanced retinopathy or kidney failure; - Resistant hypertension; - History of cardiovascular event.

Study Design


Intervention

Other:
Recreational Futsal
Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.

Locations

Country Name City State
Portugal University of Maia Maia

Sponsors (2)

Lead Sponsor Collaborator
University Institute of Maia University of Southern Denmark

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Between-groups differences in systolic blood pressure Casual (resting) measures of systolic blood pressure (mmHg) will be measured in triplicate over the brachial artery of the non-dominant arm after 5 minutes of quiet rest, with 1 minute of recovery between each measure, using an automated oscillometric sphygmomanometer. 3 months
Primary Between-groups differences in diastolic blood pressure Casual (resting) measures of diastolic blood pressure (mmHg) will be measured in triplicate over the brachial artery of the non-dominant arm after 5 minutes of quiet rest, with 1 minute of recovery between each measure, using an automated oscillometric sphygmomanometer. 3 months
Secondary Between-groups differences in systolic blood pressure Casual (resting) measures of systolic blood pressure (mmHg) will be measured in triplicate over the brachial artery of the non-dominant arm after 5 minutes of quiet rest, with 1 minute of recovery between each measure, using an automated oscillometric sphygmomanometer. 4 months
Secondary Between-groups differences in diastolic blood pressure Casual (resting) measures of diastolic blood pressure (mmHg) will be measured in triplicate over the brachial artery of the non-dominant arm after 5 minutes of quiet rest, with 1 minute of recovery between each measure, using an automated oscillometric sphygmomanometer. 4 months
Secondary Between-groups differences in mean blood pressure Casual (resting) blood pressure (mmHg) will be measured in triplicate over the brachial artery of the non-dominant arm after 5 minutes of quiet rest, with 1 minute of recovery between each measure, using an automated oscillometric sphygmomanometer. 3 months
Secondary Between-groups differences in mean blood pressure Casual (resting) blood pressure (mmHg) will be measured in triplicate over the brachial artery of the non-dominant arm after 5 minutes of quiet rest, with 1 minute of recovery between each measure, using an automated oscillometric sphygmomanometer. 4 months
Secondary Between-groups differences in total cholesterol Will be analysed using standardised methods, using relevant commercial enzymatic test kits. 3 months
Secondary Between-groups differences in total cholesterol Will be analysed using standardised methods, using relevant commercial enzymatic test kits. 4 months
Secondary Between-groups differences in high-density lipoprotein cholesterol Will be analysed using standardised methods, using relevant commercial enzymatic test kits. 3 months
Secondary Between-groups differences in high-density lipoprotein cholesterol Will be analysed using standardised methods, using relevant commercial enzymatic test kits. 4 months
Secondary Between-groups differences in low-density lipoprotein cholesterol Will be analysed using standardised methods, using relevant commercial enzymatic test kits. 3 months
Secondary Between-groups differences in low-density lipoprotein cholesterol Will be analysed using standardised methods, using relevant commercial enzymatic test kits. 4 months
Secondary Between-groups differences in triglycerides Will be analysed using standardised methods, using relevant commercial enzymatic test kits. 3 months
Secondary Between-groups differences in triglycerides Will be analysed using standardised methods, using relevant commercial enzymatic test kits. 4 months
Secondary Between-groups differences in glycosylated hemoglobin Will be analysed using standardised methods, using relevant commercial enzymatic test kits. 3 months
Secondary Between-groups differences in glycosylated hemoglobin Will be analysed using standardised methods, using relevant commercial enzymatic test kits. 4 months
Secondary Between-groups differences in resting heart rate Number of heart beats per minute, measured by heart rate monitors. 3 months
Secondary Between-groups differences in resting heart rate Number of heart beats per minute, measured by heart rate monitors. 4months
Secondary Between-groups differences in maximum oxygen consumption Determined by pulmonary gas exchange measurements. 3 months
Secondary Between-groups differences in maximum oxygen consumption Determined by pulmonary gas exchange measurements. 4 months
Secondary Between-groups differences in aerobic performance (Yo-Yo Intermittent Endurance Level 1 Test) Number of meters covered. 3 months
Secondary Between-groups differences in aerobic performance (Yo-Yo Intermittent Endurance Level 1 Test) Number of meters covered. 4 months
Secondary Between-groups differences in body mass index Defined as a person's weight in kilograms divided by the square of the person's height in metres (kg/m2) 3 months
Secondary Between-groups differences in body mass index Defined as a person's weight in kilograms divided by the square of the person's height in metres (kg/m2) 4 months
Secondary Between-groups differences in bone density (measured by DEXA in g/cm2) bone density measured by Dual Energy X-ray Absorptiometry. Bone mineral density is expressed as absolute values (g / cm2 - grams of bone mineral content per area or analyzed bone cm2). 3 months
Secondary Between-groups differences in bone density (measured by DEXA in g/cm2) bone density measured by Dual Energy X-ray Absorptiometry. Bone mineral density is expressed as absolute values (g / cm2 - grams of bone mineral content per area or analyzed bone cm2). 4 months
Secondary Between-groups differences in bone content (measured by DEXA in grams) bone density measured by Dual Energy X-ray Absorptiometry. Bone mineral density is expressed as absolute values (grams) 3 months
Secondary Between-groups differences in bone content (measured by DEXA in grams) bone density measured by Dual Energy X-ray Absorptiometry. Bone mineral density is expressed as absolute values (grams) 4 months
Secondary Between-groups differences in lean mass (measured by DEXA in kg) measured by Dual Energy X-ray Absorptiometry (kg) 3 months
Secondary Between-groups differences in lean mass (measured by DEXA in kg) measured by Dual Energy X-ray Absorptiometry (kg) 4 months
Secondary Between-groups differences in body fat (measured by DEXA in %) measured by Dual Energy X-ray Absorptiometry (%) 3 months
Secondary Between-groups differences in body fat (measured by DEXA in %) measured by Dual Energy X-ray Absorptiometry (%) 4 months
Secondary Between-groups differences in body mass (measured by DEXA in kg) measured by Dual Energy X-ray Absorptiometry (kg) 3 months
Secondary Between-groups differences in body mass (measured by DEXA in kg) measured by Dual Energy X-ray Absorptiometry (kg) 4 months
Secondary Between-groups differences in postural balance measured by a modified Flamingo test 3 months
Secondary Between-groups differences in postural balance measured by a modified Flamingo test 4 months
Secondary Between-groups differences in lower body strength measured by a counter-movement jump test 3 months
Secondary Between-groups differences in lower body strength measured by a counter-movement jump test 4 months
Secondary Between-groups differences in quality of life measured by WHOQOL-BREF questionnaire 3 months
Secondary Between-groups differences in quality of life measured by WHOQOL-BREF questionnaire 4 months
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A